Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Malignant Germ Cell Tumor: early-phase trial registry
1 of 8 indexed Recurrent Malignant Germ Cell Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,179 of 28,963 conditions by registered trial count.
8 US clinical trials · 1 currently recruiting · #2,179 of 28,963 conditions by registered trial count
Recurrent Malignant Germ Cell Tumor: 8 US clinical trials tracked, 1 recruiting.
Recurrent Malignant Germ Cell Tumor is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Open enrollment, early-phase tilt
Recurrent Malignant Germ Cell Tumor has 8 registered US clinical trials, 1 of them open to new participants right now, about 13% of the total.
- 1
- recruiting participants now
- 13%
- of trials open to enrollment
- 0
- in Phase 3-4 (later-stage)
- 7
- top sponsor: National Cancer Institute (NCI)
Corpus placement: #2,179 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Recurrent Malignant Germ Cell Tumor on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Malignant Germ Cell Tumor is recruiting below its size-band peers.
1 of 8 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Malignant Germ Cell Tumor research.
National Cancer Institute (NCI) accounts for 7 of 8 trials (87.5%). 2 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Malignant Germ Cell Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 13 among the 8 trials that report a genuine target (sentinel values excluded). 8 of those (100%) plan for fewer than 100 participants.
-
Recurrent Malignant Germ Cell Tumor research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
NCT04901702
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03698994
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03213652
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03213704
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
NCT04284774
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT04195555
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
NCT04320888
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03526250
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Recurrent Malignant Germ Cell Tumor right now
1 recruiting of 8 indexed (13% open).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top sponsor: National Cancer Institute (NCI) (7 trials), 1 other listed. 8 shown below, recruiting first. #2,179 of 28,963 conditions by registered trial count.
Why a small condition index still matters
Thin indexes still surface the registry rows that exist for this label. Counts stay small when ClinicalTrials.gov lists few studies under the condition string, not because this page omits rows. Verify any enrollment decision on ClinicalTrials.gov and with a clinician.
Frequently Asked Questions
How many clinical trials are there for Recurrent Malignant Germ Cell Tumor?
PlainTrial tracks 8 US clinical trials for Recurrent Malignant Germ Cell Tumor, of which 1 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Recurrent Malignant Germ Cell Tumor?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.